dc.contributor.author | Karita, E | |
dc.contributor.author | Price, M | |
dc.contributor.author | Hunter, E | |
dc.contributor.author | Chomba, E | |
dc.contributor.author | Allen, S | |
dc.contributor.author | Fei, L | |
dc.contributor.author | Kamali, A | |
dc.contributor.author | Sanders, EJ | |
dc.contributor.author | Anzala, O | |
dc.contributor.author | Katende, M | |
dc.contributor.author | Ketter, N | |
dc.contributor.author | IAVI Collaborative Seroprevalence and Incidence Study Team | |
dc.date.accessioned | 2013-07-19T10:15:44Z | |
dc.date.available | 2013-07-19T10:15:44Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | AIDS. 2007 Feb 19;21(4):403-8. | en |
dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/17301558 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/49419 | |
dc.description.abstract | BACKGROUND:
The identification of populations at risk of HIV infection is a priority for trials of preventive technologies, including HIV vaccines. To quantify incidence traditionally requires laborious and expensive prospective studies.
METHODS:
The BED IgG-Capture enzyme immunoassay (EIA) was developed to estimate HIV-1 incidence using cross-sectional data by measuring increasing levels of HIV-specific IgG as a proportion of total IgG. To evaluate this assay, we tested 189 seroconversion samples taken at 3-monthly intervals from 15 Rwandan and 26 Zambian volunteers with known time of infection and cross-sectional specimens from 617 Kenyan and Ugandan volunteers with prevalent infection.
RESULTS:
The BED-EIA-estimated incidence in Uganda was unexpectedly high, at 6.1%/year [95% confidence interval (CI) 4.2-8.0] in Masaka and 6.0%/year (95% CI 4.3-7.7) in Kakira. Prospective incidence data in Masaka from the same population was 1.7%/year before and 1.4%/year after the study. Kenyan estimates were 3.5%/year in Kilifi (95% CI 2.1-4.9) and 3.4%/year in Nairobi (95% CI 1.5-5.3). From the Rwandan and Zambian data, the sensitivity of the assay was 81.2% and the specificity was 67.8%. After approximately one year, subjects misclassified as recently infected tended to have lower plasma viral loads compared with those not misclassified as recent (median copies/ml 14 773 versus 93 560; P = 0.02). Clinical presentation, sex and HIV subtype were not significantly associated with BED-EIA misclassification in seroconverter samples.
CONCLUSION:
These data suggest that this assay does not perform reliably in all populations. Further research is warranted before using this assay to estimate incidence from prevalent HIV samples. | en |
dc.language.iso | en | en |
dc.publisher | University of Nairobi | en |
dc.title | Investigating The Utility Of The Hiv-1 Bed Capture Enzyme Immunoassay Using Cross-sectional And Longitudinal Seroconverter Specimens From Africa. | en |
dc.type | Article | en |
local.publisher | Department of Medical Microbiology | en |